{"id":"aav2-gdnf-gene-therapy","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Flu-like symptoms"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The delivered GDNF protein acts as a neurotrophic factor, supporting the health and function of dopaminergic neurons in the brain. This can potentially slow or halt the progression of neurodegenerative diseases such as Parkinson's disease.","oneSentence":"AAV2-GDNF gene therapy delivers a viral vector carrying the GDNF gene to the brain, where it is expressed and promotes the survival and growth of dopaminergic neurons.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:07.380Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"}]},"trialDetails":[{"nctId":"NCT01621581","phase":"PHASE1","title":"AAV2-GDNF for Advanced Parkinson s Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2013-03-13","conditions":"Parkinson's Disease","enrollment":25},{"nctId":"NCT04680065","phase":"PHASE1","title":"GDNF Gene Therapy for Multiple System Atrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brain Neurotherapy Bio, Inc.","startDate":"2023-10-03","conditions":"Multiple System Atrophy","enrollment":9},{"nctId":"NCT06285643","phase":"PHASE2","title":"A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)","status":"RECRUITING","sponsor":"AskBio Inc","startDate":"2024-06-11","conditions":"Parkinson Disease","enrollment":127},{"nctId":"NCT04167540","phase":"PHASE1","title":"GDNF Gene Therapy for Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brain Neurotherapy Bio, Inc.","startDate":"2020-04-01","conditions":"Parkinson's Disease","enrollment":11},{"nctId":"NCT00985517","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease","status":"COMPLETED","sponsor":"Sangamo Therapeutics","startDate":"2009-10-29","conditions":"Idiopathic Parkinson's Disease","enrollment":57}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Biological"],"phase":"phase_2","status":"active","brandName":"AAV2-GDNF gene therapy","genericName":"AAV2-GDNF gene therapy","companyName":"Brain Neurotherapy Bio, Inc.","companyId":"brain-neurotherapy-bio-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"AAV2-GDNF gene therapy delivers a viral vector carrying the GDNF gene to the brain, where it is expressed and promotes the survival and growth of dopaminergic neurons. Used for Parkinson's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}